Categories
Change Password!
Reset Password!
This study aimed to evaluate the safety and efficacy of IL-17 inhibitors (comprising secukinumab or ixekizumab) in active ankylosing spondylitis patients.
In this review, 1722 patients
registered in randomized, double-blind placebo-controlled trials who received
IL-17 inhibitor portrayed superior improvements in ASAS20/40 response rates as
compared to placebo making it an effective option for active ankylosing
spondylitis.
This study aimed to evaluate the safety and efficacy of
IL-17 inhibitors (comprising secukinumab or ixekizumab) in active ankylosing
spondylitis patients.
The literature search for the systematic
review included the randomized controlled trials (RCTs) with patients with ankylosing spondylitis who were given IL-17
inhibitors. Safety and efficacy of the IL-17 inhibitors therapy was determined
in meta-analysis. The patients with minimum 20% improvement as per the
Assessment of Spondyloarthritis International Society (ASAS20) response
criteria at week 16 were regarded as the primary endpoint. The ASAS40 at week
16 was regarded as the secondary endpoint.
Six randomized, double-blind,
placebo-controlled trials with 1733 patients were included. Out of these, 1153
patients were given IL-17 inhibitors, while 580 patients were given placebo. The
IL-17 inhibitor treatment was found to significantly increase the ASAS20
response rate and secondary endpoint ASAS40 response rate (RR = 1.63, 95% CI
1.45 to 1.84 and RR = 2.12, 95% CI 1.75 to 2.56, respectively) as compared to
placebo. As per safety outcomes, the number of treatment-related
adverse events and non-severe infections were more (RR = 1.11, 95% CI 1.01 to
1.22 and RR = 1.82, 95% CI 1.40 to 2.37, respectively) following the IL-17
inhibitors therapy as compared to with placebo. There was no augmented
risk of added adverse events after IL-17 inhibitor therapy.
Inspite of increased risk of non-severe infections in the
active ankylosing spondylitis treatment, IL-17 inhibitors delivered promising response
rates.
Arthritis Research & Therapy
Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis
Yufeng Yin et al.
Comments (0)